TFIIS and GDOWN1 as targets for cancer therapy
The present invention concerns cancer therapy related to the targeting of at least one core transcription factor. In particular, the compositions and methods of the invention concern targeting TFIIS, GDOWN1, or both for cancer therapy. In specific aspects, TFIIS and/or GDOWN1 inhibitors are employed for breast, prostate, pancreatic, and/or lung cancer.
1. A method of inhibiting proliferation of at least one breast cancer cell in an individual, the method comprising delivering to the cell an effective amount of a composition comprising a siRNA that is 18-40 nucleotides in length that inhibits TFIIS (SEQ ID NO: 15), wherein the delivery is by direct delivery and wherein the breast cancer cell proliferation is differentially inhibited compared to non-cancerous cell proliferation.
2. The method of claim 1 , wherein the siRNA comprises SEQ ID NO:7.
3. The method of claim 1 , wherein the individual is further provided one or more additional anti-cancer therapies.
4. The method of claim 3 , wherein the additional anti-cancer therapy comprises chemotherapy.
5. A method of treating an individual with breast cancer, the method comprising delivering to the individual an effective amount of a composition comprising a siRNA that is 18-40 nucleotides in length that inhibits TFIIS (SEQ ID NO: 15), wherein the delivery is by direct delivery and wherein the breast cancer proliferation is differentially inhibited compared to non-cancerous cell proliferation.